Melanoma TRP2 CTL Epitope Vaccine SCIB1

A proprietary DNA-based cancer vaccine that encodes a melanoma antigen tyrosinase-related protein 2 (TRP2) cytotoxic T-lymphocyte (CTL) epitope and a modified monoclonal antibody, a chimera of human IgG1/murine IgG2a with T cell mimotopes expressed within the complementarity-determining regions (CDR) of the antibodies, with potential immunostimulating and antineoplastic activities. Upon intramuscular injection and electroporation, melanoma TRP2 CTL epitope vaccine SCIB1 expresses the modified antibody. Subsequently, the Fc component of the engineered antibody targets and binds to the CD64 receptor on the dendritic cells (DCs); upon processing by DCs, the cellular immune system may be activated to induce helper T-cell and CTL immune responses against tumor cells expressing the TRP2 antigen. (NCI Thesaurus)

YOU MAY ALSO LIKE

Melanoma Theraccine

A synthetic allogeneic cancer vaccine. Melanoma theraccine typically consists of lysed melanoma cells obtained from several melanoma cell lines combined with…

Melanoma Pathway

Five distinct stages have been proposed in the evolution of melanoma on the basis of histological criteria: common acquired and congenital nevi…

Melanoma of the Uvea TNM Finding v7

A finding about one or more characteristics of melanoma of the uvea, following the rules of the TNM AJCC v7 classification…

Melanoma of the Uvea Pathologic Regional Lymph Nodes TNM Finding v7

A pathologic finding about one or more characteristics of melanoma of the uvea, following the rules of the TNM AJCC v7 classification…

Melanoma of the Uvea Pathologic Primary Tumor TNM Finding v7

A pathologic finding about one or more characteristics of melanoma of the uvea, following the rules of the TNM AJCC v7 classification…

Melanoma of the Uvea Clinical TNM Finding v7

A clinical finding about one or more characteristics of melanoma of the uvea, following the rules of the TNM AJCC v7 classification…